The clinical advisory board, chaired by Cedars Sinai Medical Center GI Motility Program and Laboratory Director Mark Pimentel, MD, is designed to support the development of IBS treatment SYN-010.
The new advisory board members include:
• William Chey, MD, director of the GI Physiology Laboratory and co-director of the Michigan Bowel Control Program at the University of Michigan in Ann Arbor
• Gail M. Corner, MD, a board-certified gastroenterologist and hepatologist with experience in the pharmaceutical industry
• Anthony J. Lembo, MD, associate professor of medicine at Harvard Medical School and director of the GI Motility Laboratory at the Beth Israel Deaconess Medical Center, both in Boston
• Philip Schoenfeld, MD, MSED, MSc, professor of medicine at the University of Michigan School of Medicine and director of the university’s Gastrointestinal Epidemiology Training Program
More articles on gastroenterology:
11 statistics on gastroenterologists & payer relationships
FDA approves combination drug Harvoni for HCV
Metropolitan Gastroenterology Group to expand outpatient office
